

CLAIMS

1. A maleate salt of AZD2171.
2. A maleate salt of AZD2171, according to claim 1, in the crystalline form, Form A.
3. A maleate salt of AZD2171, according to claim 1, in the crystalline form, Form B.
4. A maleate salt of AZD2171, according to claim 2, in the crystalline form, Form A, wherein said salt has an X-ray powder diffraction pattern with at least one specific peak at about $2\text{-theta} = 21.5^\circ$.
5. A maleate salt of AZD2171, according to claim 2, in the crystalline form, Form A, wherein said salt has an X-ray powder diffraction pattern with at least one specific peak at about $2\text{-theta} = 16.4^\circ$.
6. A maleate salt of AZD2171, according to claim 2, in the crystalline form, Form A, wherein said salt has an X-ray powder diffraction pattern with at least two specific peaks at about $2\text{-theta} = 21.5$ and 16.4° .
7. A maleate salt of AZD2171, according to claim 2, in the crystalline form, Form A, wherein said salt has an X-ray powder diffraction pattern with specific peaks at about $2\text{-theta} = 21.5, 16.4, 24.4, 20.7, 25.0, 16.9, 12.1, 22.2, 17.4$ and 17.6° .
8. A maleate salt of AZD2171, according to claim 2, in the crystalline form, Form A, wherein said salt has an X-ray powder diffraction pattern substantially the same as the X-ray powder diffraction pattern shown in Figure 5.
9. A maleate salt of AZD2171, according to claim 3, in the crystalline form, Form B, wherein said salt has an X-ray powder diffraction pattern with at least one specific peak at about $2\text{-theta} = 24.2^\circ$.

10. A maleate salt of AZD2171, according to claim 3, in the crystalline form, Form B, wherein said salt has an X-ray powder diffraction pattern with at least one specific peak at about $2\text{-}\theta = 22.7^\circ$.
11. A maleate salt of AZD2171, according to claim 3, in the crystalline form, Form B, wherein said salt has an X-ray powder diffraction pattern with at least two specific peaks at about $2\text{-}\theta = 24.2$ and 22.7° .
12. A maleate salt of AZD2171, according to claim 3, in the crystalline form, Form B, wherein said salt has an X-ray powder diffraction pattern with specific peaks at about $2\text{-}\theta = 24.2, 22.7, 15.7, 12.0, 27.1, 25.0, 17.7, 15.0, 23.1$ and 12.6° .
13. A maleate salt of AZD2171, according to claim 3, in the crystalline form, Form B, wherein said salt has an X-ray powder diffraction pattern substantially the same as the X-ray powder diffraction pattern shown in Figure 8.
14. A pharmaceutical composition which comprises a maleate salt of AZD2171 according to claim 1 in association with a pharmaceutically acceptable excipient or carrier.
15. A pharmaceutical composition according to claim 14 wherein the AZD2171 maleate salt is in the crystalline form, Form A.
16. A pharmaceutical composition according to claim 14 wherein the AZD2171 maleate salt is in the crystalline form, Form B.
17. A process for the preparation of a maleate salt of AZD2171 in the crystalline form Form A, as claimed in claim 2, which comprises:
 - (i) dissolving AZD2171 free base in an organic solvent to form a solution;
 - (ii) adding an aqueous solution of maleic acid or adding a solution of maleic acid in an organic solvent;
 - (iii) allowing spontaneous nucleation to occur;
 - (iv) slurring the mixture in a solvent until all the AZD2171 maleate is Form A; and
 - (v) isolating the crystalline solid so formed.

18. A process for the preparation of a maleate salt of AZD2171 in the crystalline form Form A, as claimed in claim 2, which comprises:

- (i) dissolving AZD2171 free base in an organic solvent to form a solution;
- (ii) adding an aqueous solution of maleic acid or adding a solution of maleic acid in an organic solvent;
- (iii) obtaining a solution and adding a seed of AZD2171 maleate Form A to initiate crystallisation of AZD2171 maleate Form A; and
- (iv) isolating the crystalline solid so formed.

19. A process for the preparation of a maleate salt of AZD2171 in the crystalline form Form B, as claimed in claim 3, which comprises:

- (i) dissolving AZD2171 maleate in an organic solvent to form a solution;
- (ii) adding the solution to a solvent in which AZD2171 maleate has a lower solubility than it does in NMP;
- (iii) crystallisation of AZD2171 maleate Form B then occurs; and
- (iv) isolating the crystalline solid so formed.

20. Use of a maleate salt of AZD2171 as claimed in claim 1 in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human being.

21. A method for producing an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal, such as a human being, in need of such treatment which comprises administering to said animal an effective amount of an AZD2171 maleate salt as claimed in claim 1.